Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) EBITDA Margin: 2015-2023

Historic EBITDA Margin for Cellectis (CLLS) over the last 9 years, with Sep 2023 value amounting to -13,336.13%.

  • Cellectis' EBITDA Margin rose 229416.00% to -13,336.13% in Q3 2023 from the same period last year, while for Sep 2023 it was -444.85%, marking a year-over-year increase of 36396.00%. This contributed to the annual value of -348.56% for FY2022, which is 8045.00% down from last year.
  • Latest data reveals that Cellectis reported EBITDA Margin of -13,336.13% as of Q3 2023, which was down 0.50% from -13,270.22% recorded in Q2 2023.
  • In the past 5 years, Cellectis' EBITDA Margin ranged from a high of 28.75% in Q1 2020 and a low of -16,856.83% during Q1 2023.
  • Over the past 3 years, Cellectis' median EBITDA Margin value was -1,755.44% (recorded in 2022), while the average stood at -5,830.56%.
  • Per our database at Business Quant, Cellectis' EBITDA Margin soared by 287,627bps in 2019 and then plummeted by 1,512,056bps in 2022.
  • Quarterly analysis of 5 years shows Cellectis' EBITDA Margin stood at -870.34% in 2019, then skyrocketed by 58,340bps to -286.94% in 2020, then soared by 4,761bps to -239.33% in 2021, then surged by 20,401bps to -35.32% in 2022, then surged by 229,416bps to -13,336.13% in 2023.
  • Its last three reported values are -13,336.13% in Q3 2023, -13,270.22% for Q2 2023, and -16,856.83% during Q1 2023.